ARS Pharmaceuticals, Inc.·4

Jan 3, 4:30 PM ET

Scott Kathleen D. 4

4 · ARS Pharmaceuticals, Inc. · Filed Jan 3, 2025

Insider Transaction Report

Form 4
Period: 2025-01-02
Scott Kathleen D.
Chief Financial Officer
Transactions
  • Award

    Stock option (right to buy)

    2025-01-02+176,700176,700 total
    Exercise: $10.71Exp: 2035-01-01Common Stock (176,700 underlying)
Footnotes (1)
  • [F1]The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025.

Documents

1 file
  • 4
    form4-01032025_040124.xmlPrimary